Vaxart (NASDAQ: VXRT) is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on developing oral recombinant protein vaccines and therapeutics using its proprietary VAAST (Vaxart Adjuvant System Technology) platform. Founded in 2007, the company is pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases, offering a potentially revolutionary advance in immunization technology[1].
From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases. The company aims to create safe, effective, and accessible solutions that protect communities worldwide.
Vaxart's oral pill vaccines leverage proprietary technology with several key advantages:
| Feature | Benefit |
|---|---|
| Oral delivery | Tablet form factor eliminating needles |
| Room temperature stability | Enhanced logistics and storage capabilities |
| Mucosal immunity | Stimulates IgA antibodies in respiratory and gut tracts |
| Systemic immunity | Generates protective circulating antibodies |
| Patient compliance | No injection required |
| Product | Indication | Development Phase |
|---|---|---|
| COVID-19 Vaccine | SARS-CoV-2 prevention | Clinical development |
| Norovirus Vaccine | Norovirus prevention | Clinical development |
| Influenza Vaccine | Flu prevention | Clinical development |
| HPV Vaccine | Human papillomavirus | Preclinical |
| Alzheimer's Vaccine | Amyloid-beta targeting | Research |
Vaxart's oral COVID-19 vaccine candidate leverages the VAAST platform to generate mucosal and systemic immunity against SARS-CoV-2. The oral delivery approach may offer advantages in generating immunity at the primary site of viral entry (the respiratory tract).
Norovirus is a leading cause of acute gastroenteritis worldwide. Vaxart's oral norovirus vaccine aims to generate mucosal immunity in the gut, the primary site of norovirus infection.
Seasonal flu remains a significant public health burden. Vaxart's oral influenza vaccine candidate is designed to generate broad protection against multiple flu strains.
Vaxart has been developing an oral amyloid-beta vaccine candidate for Alzheimer's disease. The oral delivery approach aims to generate immune responses against amyloid-beta plaques while potentially improving safety profile compared to injectable antibodies[2].
Key aspects of the Alzheimer's vaccine program:
| Item | Detail |
|---|---|
| Headquarters | South San Francisco, California |
| Founded | 2007 |
| Stock exchange | NASDAQ |
| Ticker symbol | VXRT |
| Focus | Oral vaccines and therapeutics |
Vaxart maintains partnerships to accelerate development of their pipeline:
Manufacturing partnerships for clinical supply
Academic collaborations for platform optimization
Government and non-governmental organizations for global health applications